Association of body mass index and osteoarthritis with healthcare expenditures and utilization.

Osteoarthritis is highly prevalent and, on aggregate, is one of the largest contributors to US spending on hospital-based health care. This study sought to examine body mass index (BMI)-related variation in the association of osteoarthritis with healthcare utilization and expenditures. This is a retrospective study using administrative insurance claims linked to electronic health records. Study patients were aged ≥ 18 years with ≥1 BMI measurement recorded in 2014, with the first ( A total of 256 459 patients (median age = 56 y) met study eligibility criteria; 14.8% (38 050) had osteoarthritis. In multivariable analyses, the adjusted prevalence of osteoarthritis increased with increasing BMI (12.7% in patients who were overweight [25.0-29.9 kg m The prevalence and economic burden of osteoarthritis grow with increasing BMI; primary prevention of weight-related osteoarthritis and secondary weight management may help to alleviate this burden.

Informations de copyright

© 2019 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Stephen Johnston is an employee and stockholder of Johnson & Johnson. Eric Ammann is an employee of Johnson & Johnson. Robin Scamuffa was an employee and stockholder of Ethicon, a Johnson & Johnson company, at the time of this research. Jonathan Samuels has no financial interests to disclose. Andrew Stokes has received research funding from Ethicon, a Johnson & Johnson company, for an unrelated study. Elliott Fegelman was an employee and stockholder of Ethicon, a Johnson & Johnson company, at the time of this research. Carine Hsiao was an employee and stockholder of Ethicon, a Johnson & Johnson company, at the time of this research.